Critics are alarmed about a news article published on the front page of the New York Times and headlined: A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.
Really? We all fervently wish for a cure for the devastation of diabetes, especially type 1 which starts in childhood. But the problem, savvy readers found, is that the report falls far short of reasonable standards for a global news organization to trumpet the “c” word — cure.
Dig into the 2,000-word piece and skepticism should be the watch word. That’s because reporter Gina Kolata focused on the earliest outcomes of a stem-cell treatment for type 1 diabetes undergoing clinical trials. So far, 17 patients have been treated. One patient, so far, has experienced positive results that have sustained for six months. The New York Times gave no clue about the outcomes for the 16 others.